These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 3794418)
21. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder]. Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955 [TBL] [Abstract][Full Text] [Related]
22. Use of H(2) (15)O-PET for investigating perfusion changes in pelvic tumors due to regional hyperthermia. Lüdemann L; Sreenivasa G; Amthauer H; Michel R; Gellermann J; Wust P Int J Hyperthermia; 2009 Jun; 25(4):299-308. PubMed ID: 19670097 [TBL] [Abstract][Full Text] [Related]
23. Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation. Hauck ML; Zalutsky MR Int J Hyperthermia; 2005 Feb; 21(1):13-27. PubMed ID: 15764348 [TBL] [Abstract][Full Text] [Related]
24. Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy. Chaplin DJ; Acker BD; Horsman MR Biomed Biochim Acta; 1989; 48(2-3):S264-8. PubMed ID: 2730621 [TBL] [Abstract][Full Text] [Related]
25. Regression of canine transmissible venereal sarcoma. Yang TJ J Am Vet Med Assoc; 1987 Jul; 191(1):6. PubMed ID: 3610780 [No Abstract] [Full Text] [Related]
26. Effect of 8-MHz radiofrequency-capacitive regional hyperthermia with strong superficial cooling for unresectable or recurrent colorectal cancer. Ohguri T; Imada H; Yahara K; Kakeda S; Tomimatsu A; Kato F; Nomoto S; Terashima H; Korogi Y Int J Hyperthermia; 2004 Aug; 20(5):465-75. PubMed ID: 15277020 [TBL] [Abstract][Full Text] [Related]
27. Prospective treatment planning to improve locoregional hyperthermia for oesophageal cancer. Kok HP; van Haaren PM; van de Kamer JB; Zum Vörde Sive Vörding PJ; Wiersma J; Hulshof MC; Geijsen ED; van Lanschot JJ; Crezee J Int J Hyperthermia; 2006 Aug; 22(5):375-89. PubMed ID: 16891240 [TBL] [Abstract][Full Text] [Related]
28. MicroPET-compatible, small animal hyperthermia ultrasound system (SAHUS) for sustainable, collimated and controlled hyperthermia of subcutaneously implanted tumours. Singh AK; Moros EG; Novak P; Straube W; Zeug A; Locke JE; Myerson RJ Int J Hyperthermia; 2004 Feb; 20(1):32-44. PubMed ID: 14612312 [TBL] [Abstract][Full Text] [Related]
29. Tissue physiology and the response to heat. Horsman MR Int J Hyperthermia; 2006 May; 22(3):197-203. PubMed ID: 16754339 [TBL] [Abstract][Full Text] [Related]
30. Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Thrall DE; Larue SM; Pruitt AF; Case B; Dewhirst MW Int J Hyperthermia; 2006 Aug; 22(5):365-73. PubMed ID: 16891239 [TBL] [Abstract][Full Text] [Related]
31. Hyperthermia of pet animal tumours with self-regulating ferromagnetic thermoseeds. Brezovich IA; Lilly MB; Meredith RF; Weppelmann B; Henderson RA; Brawner W; Salter MM Int J Hyperthermia; 1990; 6(1):117-30. PubMed ID: 2299225 [TBL] [Abstract][Full Text] [Related]
32. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851 [TBL] [Abstract][Full Text] [Related]
33. Vincristine for treatment of transmissible venereal tumor in the dog--. Calvert CA; Leifer CE; MacEwen EG J Am Vet Med Assoc; 1982 Jul; 181(2):163-4. PubMed ID: 6749780 [No Abstract] [Full Text] [Related]
34. Follow-up on chemotherapy of venereal tumors. Brown NO; MacEwen EG; Clavert C J Am Vet Med Assoc; 1980 Oct; 177(8):676. PubMed ID: 7440361 [No Abstract] [Full Text] [Related]
35. Assessment of the temperature distribution during hyperthermia treatment by isolated extremity perfusion. Gantenberg J; Mumme A; Zumtobel V; Werner J Int J Hyperthermia; 2001; 17(3):189-206. PubMed ID: 11347726 [TBL] [Abstract][Full Text] [Related]
36. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Hokland SL; Horsman MR Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290 [TBL] [Abstract][Full Text] [Related]
37. Use of combined systemic hypothermia and local heat treatment to enhance temperature differences between tumor and normal tissues. Babbs CF; Voorhees WD; Clark RR; DeWitt DP Med Instrum; 1985; 19(1):27-33. PubMed ID: 3990596 [TBL] [Abstract][Full Text] [Related]